Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Drug 601 (Anti-VEGF mAb) in Wet AMD
NCT04468997Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 601 in exudative macular degeneration (6 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Status: unknown.
02
Drugs
601
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04468997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468997.